A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-PART STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORALLY ADMINISTERED DEUCRICTIBANT XR TABLET FOR PROPHYLAXIS AND DEUCRICTIBANT SOFT CAPSULE FOR ON-DEMAND TREATMENT OF ANGIOEDEMA ATTACKS IN ADULTS WITH ACQUIRED ANGIOEDEMA DUE TO C1¿INHIBITOR DEFICIENCY (CREAATE)

Registry ID

PHA022121-C308

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

PHARVARIS NETHERLANDS B.V.

Last update

2025-09-19

Conditions

• ANGIOEDEMA

Related clinical trials

• CLOUD-R HAE REGISTRY

View on source registry